ESMO Voices from China | Professor Qingqing Cai: Rocbrutinib Plus R-CHOP as First-Line Treatment for Non-GCB DLBCL—Deep Responses and a Favorable Long-Term Safety Profile with No Atrial Fibrillation or Major Bleeding
Non-germinal center B-cell-like (non-GCB) diffuse large B-cell lymphoma (DLBCL) is characterized by substantial molecular heterogeneity. Compared with the GCB subtype, it generally responds less favorably to conventional immunochemotherapy and is associated with poorer outcomes, making it a challenging subtype in clinical practice. At the 2026 European Society for Medical Oncology (ESMO) Congress, Professor Qingqing Cai's team from Sun Yat-sen University Cancer Center presented data from a multicenter Phase Ib study (1457O) evaluating the safety and preliminary efficacy of rocbrutinib, a novel fourth-generation Bruton tyrosine kinase (BTK) inhibitor, in combination with R-CHOP as first-line treatment for B-cell lymphoma. The study demonstrated an objective response rate (ORR) of 100% and a complete response (CR) rate of 86.7% among patients with newly diagnosed non-GCB DLBCL, with no cases of atrial fibrillation or severe bleeding observed. In this article, we invited Professor Qingqing Cai to provide an in-depth interpretation of the translational value and future research directions of this regimen, covering its pharmacological mechanisms, minimal residual disease (MRD)-guided strategies, and the future clinical development landscape.









